{"id":241408,"date":"2026-01-28T18:35:17","date_gmt":"2026-01-28T18:35:17","guid":{"rendered":"https:\/\/businesnewswire.com\/?p=164660"},"modified":"2026-01-28T18:35:17","modified_gmt":"2026-01-28T18:35:17","slug":"ubigene-showcases-crispr-iscreen-platform-for-precision-crispr-screening","status":"publish","type":"post","link":"https:\/\/ipsnews.net\/business\/2026\/01\/28\/ubigene-showcases-crispr-iscreen-platform-for-precision-crispr-screening\/","title":{"rendered":"Ubigene Showcases CRISPR-iScreen\u2122 Platform for Precision CRISPR Screening"},"content":{"rendered":"

NEW YORK, January 2026<\/b> \u2013 <\/span>Ubigene<\/b>, a global biotechnology innovator specializing in precision gene editing solutions, today highlights its proprietary <\/span>CRISPR-iScreen\"\u2122\" platform<\/b>, a high-efficiency CRISPR screening technology designed to support both <\/span>in vivo and in vitro functional genomics research<\/b>. The platform addresses growing industry demand for more reliable, scalable, and biologically relevant screening strategies in translational research and drug target discovery.<\/span><\/p>\n

\"\"<\/p>\n

As <\/span>CRISPR gene editing<\/b><\/a> continues to transform early-stage research, scientists increasingly rely on large-scale functional screens to uncover gene function and therapeutic vulnerabilities. While in vitro screening remains a critical discovery tool, the complexity of biological systems has driven greater adoption of <\/span>in vivo CRISPR screening<\/b> to validate targets under physiologically relevant conditions. Ubigene\u2019s CRISPR-iScreen\"\u2122\" platform was developed to support this multi-layered approach, combining experimental robustness with analytical accessibility.<\/span><\/p>\n

Proprietary CRISPR-iScreen\"\u2122\" Technology Enables High-Quality Screening Data<\/span><\/h2>\n

CRISPR-iScreen\"\u2122\" is independently developed by Ubigene to deliver <\/span>high-efficiency, high-precision CRISPR screening<\/b> for gene function characterization and mechanistic studies. Central to the platform is Ubigene\u2019s <\/span>library-specific competent cell technology<\/b>, which achieves exceptional DNA uptake efficiency and minimizes background mutations during plasmid amplification. As a result, CRISPR libraries generated through this system demonstrate <\/span>greater than 99% coverage<\/b> with <\/span>less than 10% uniformity variation<\/b>, supporting reproducible and statistically robust screening outcomes.<\/span><\/p>\n

In addition, Ubigene employs an <\/span>exclusive cell pool preparation process<\/b> optimized for large-scale library production. This standardized workflow minimizes batch-to-batch variability while maintaining up to <\/span>99% library coverage<\/b>, providing a consistent foundation for both exploratory and validation-stage CRISPR screening projects.<\/span><\/p>\n

Flexible Screening Platforms for Diverse Experimental Designs<\/span><\/h2>\n

Ubigene offers <\/span>end-to-end CRISPR screening services<\/b> spanning <\/span>in vitro and in vivo models<\/b>, enabling researchers to tailor experimental designs to specific biological questions. The screening platform supports a broad range of experimental conditions, including compound treatment, serial passaging, viral infection models, and <\/span>flow cytometry\u2013based selection strategies<\/b>. Multiple enrichment and selection options allow researchers to optimize workflows for oncology, immunology, functional genomics, and other research areas where gene behavior is strongly context-dependent.<\/span><\/p>\n

This flexibility reflects a broader industry shift toward integrated research strategies that combine computational analysis, in vitro discovery, and in vivo validation to improve confidence in downstream research decisions.<\/span><\/p>\n

iScreenAnlys\"\u2122\" Simplifies CRISPR Screening Data Analysis<\/span><\/h2>\n

To further accelerate discovery, Ubigene developed <\/span>iScreenAnlys\"\u2122\"<\/b>, an interactive CRISPR screening data analysis system designed for accessibility and efficiency. The platform requires <\/span>no coding or bioinformatics expertise<\/b>, offering an intuitive interface that integrates multiple statistical algorithms and customizable visualization tools. Researchers can rapidly build personalized analysis pipelines and generate <\/span>publication-ready figures and reports<\/b>, streamlining interpretation of complex screening datasets.<\/span><\/p>\n

Extensive CRISPR Library Resources Available<\/span><\/h2>\n

Ubigene maintains one of the industry\u2019s most comprehensive <\/span>CRISPR library inventories<\/b>, supporting rapid project initiation and scalability. Available resources include:<\/span><\/p>\n